iLite® Type I IFN FAST Assay Ready Cells
BM4049
The iLite® Type I IFN FAST assay offers accelerated quantification of type I interferon signaling with a shortened incubation time. Ideal for high-throughput functional antibody screening and antiviral research.
- High sensitivity and large dynamic range
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
- Normalization of cell counts and serum matrix effects using a second reporter gene
Product Overview
iLite® IFN type I FAST Assay Ready Cells are human embryonic kidney HEK293 cells (used under a license obtained from AdVec Inc). They have been genetically engineered and optimized to be responsive to type I interferon, resulting in a proportional expression of Firefly Luciferase.
This product can be used for studies of type I interferon (IFNα and IFNβ) in test samples, including human serum.
iLite® IFN type I FAST Assay Ready Cells also contain a Renilla Luciferase internal standardization gene under the control of a constitutive promoter that renders assay results independent of cell number and provides a means for correcting for cytotoxic effects that may be encountered in some biological samples.
FOR RESEARCH USE ONLY
How it works
The function of iLite assays
iLite cells have receptors on the cell surface that can bind to the marker under study.
What's in the box?
>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM4049 |
| Assay target | Type I IFN |
| Size | 1 vial corresponding to one 96 well plate (1 vial (2.5mL)) |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
| Assay time | 5h |
Documents
Application Note
Downloads
Navigating the Complexities of Cell-based Assays in GMP QC Testing: The Journey to Robust Assays
Read post
The Value of Assay-Ready Cells in Providing Biologically Relevant Data for Robust Therapeutic Develo...
Read post
How Biosimilars Are Expanding Options for Patient Care
Read post
Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeuti...
Read post
The Future of Drug Development for Complex Pathologies: Versatile Cell-based Assays and Customizable...
Read post
Webinar - Advancements in GMP QC Testing: A Comprehensive Guide to Cell-Based Assays
Read post
